Rossing P - Search Results

1

Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.

Pena MJ, Jankowski J, Heinze G, Kohl M, Heinzel A, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D, Heerspink HJ, Jankowski V. Pena MJ, et al. Among authors: rossing p. J Hypertens. 2015 Oct;33(10):2123-32. doi: 10.1097/HJH.0000000000000685. J Hypertens. 2015. PMID: 26237555

2

Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension.

Gall MA, Rossing P, Skøtt P, Hommel E, Mathiesen ER, Gerdes LU, Lauritzen M, Vølund A, Faergeman O, Beck-Nielsen H, et al. Gall MA, et al. Among authors: rossing p. Am J Hypertens. 1992 May;5(5 Pt 1):257-65. doi: 10.1093/ajh/5.5.257. Am J Hypertens. 1992. PMID: 1581012 Clinical Trial.

3

Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.

Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes Care. 1994 Nov;17(11):1247-51. doi: 10.2337/diacare.17.11.1247. Diabetes Care. 1994. PMID: 7821162

4

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

Parving HH, Rossing P. Parving HH, et al. Among authors: rossing p. Curr Opin Nephrol Hypertens. 1994 May;3(3):292-300. doi: 10.1097/00041552-199405000-00010. Curr Opin Nephrol Hypertens. 1994. PMID: 7922255 Review.

5

Renal protection in diabetes: an emerging role for calcium antagonists.

Parving HH, Tarnow L, Rossing P. Parving HH, et al. Among authors: rossing p. J Hypertens Suppl. 1996 Nov;14(4):S21-5. doi: 10.1097/00004872-199606234-00005. J Hypertens Suppl. 1996. PMID: 8986939 Review.

6

Renal protection in diabetes--an emerging role for calcium antagonists.

Parving HH, Tarnow L, Rossing P. Parving HH, et al. Among authors: rossing p. Cardiology. 1997;88 Suppl 3:56-62. doi: 10.1159/000177509. Cardiology. 1997. PMID: 9397296 Review.

7

Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.

Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, Navis G. Bos H, et al. Among authors: rossing p. Kidney Int Suppl. 2000 Apr;75:S32-7. Kidney Int Suppl. 2000. PMID: 10828759 Free article.

8

Renoprotection with and without blood pressure reduction.

Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Laverman GD, et al. Among authors: rossing p. Kidney Int Suppl. 2005 Apr;(94):S54-9. doi: 10.1111/j.1523-1755.2005.09414.x. Kidney Int Suppl. 2005. PMID: 15752241 Free article. Clinical Trial.

9

Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?

Rossing P, Parving HH, de Zeeuw D. Rossing P, et al. Nephrol Dial Transplant. 2006 Sep;21(9):2354-7; discussion 2357-8. doi: 10.1093/ndt/gfl454. Nephrol Dial Transplant. 2006. PMID: 16928724 Review. No abstract available.

10

Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.

Astrup AS, Nielsen FS, Rossing P, Ali S, Kastrup J, Smidt UM, Parving HH. Astrup AS, et al. Among authors: rossing p. J Hypertens. 2007 Dec;25(12):2479-85. doi: 10.1097/HJH.0b013e3282f06428. J Hypertens. 2007. PMID: 17984670

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

783 results

Search Page

Filters